ADDED
Aggregate market value of voting and non-voting common equity of Medtronic plc held by non-affiliates of the registrant as of October 25, 2024, based on the closing price of $90.59 as reported on the New York Stock Exchange: approximately $ 116.2 billion.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 106 9A.
Our Mission to alleviate pain, restore health, and extend life empowers us to engineer the extraordinary and deliver better outcomes for our world.
We are a company of dedication, honesty, integrity, and service.
Building on this strong foundation, we are embracing our role as a healthcare technology leader and evolving our business strategy in three key areas: Accelerate innovation-driven growth: The combination of our attractive end markets, recent product launches and robust pipeline is expected to enable continued strong revenue growth.
Deliver superior outcomes and better experiences for patients and providers: We listen to our patients and customers to better understand the challenges they face.
Turn data, artificial intelligence (AI), and automation into action: We are confident in our ability to maximize new technology, AI, and data and analytics to tailor therapies in real-time, facilitating remote monitoring and care delivery that conveniently manages conditions, and creates new standards of care.
Cardiac Rhythm Heart Failure Our Cardiac Rhythm Heart Failure division includes the following Operating Units: Cardiac Rhythm Management and Cardiac Ablation Solutions.
The 3830 lead, with His-bundle and left bundle branch capabilities, effectively covers all current forms of conduction system pacing and sensing.
The portfolio includes the Arctic Front Advanced Cardiac Cryoblation System, PulseSelect single shot Pulsed Field Ablation catheter, the Sphere-9 focal catheter, providing high density mapping capabilities combined with dual radio frequency and pulsed field energies to deliver ablation lesions, and Affera Mapping and Navigation System with Prism-1 software aimed at integrating clinical information to improve patient outcomes.
REMOVED
Aggregate market value of voting and non-voting common equity of Medtronic plc held by non-affiliates of the registrant as of October 27, 2023, based on the closing price of $69.43 as reported on the New York Stock Exchange: approximately $ 92.4 billion.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 103 9A.
Our Mission to alleviate pain, restore health, and extend life empowers insight-driven care and better outcomes for our world.
We remain committed to being recognized as a company of dedication, honesty, integrity, and service.
Building on this strong foundation, we are embracing our role as a healthcare technology leader and evolving our business strategy in four key areas: Leveraging our pipeline to accelerate revenue growth: The combination of our end markets, recent product launches and robust pipeline is expected to continue accelerating our growth over both the near-and long-term.
Serving more patients by accelerating innovation driven growth and delivering shareholder value: We listen to our patients and customers to better understand the challenges they face.
Creating and disrupting markets with our technology: We are confident in our ability to maximize new technology, artificial intelligence (AI), and data and analytics to tailor therapies in real-time, facilitating remote monitoring and care delivery that conveniently manages conditions, and creates new standards of care.
Empowering our operating units to be more nimble and more competitive: Our operating model is organized to accelerate decision making, improve commercial execution, and more effectively leverage the scale of our company.
The 3830 lead, previously labeled for His-bundle pacing, has now been expanded to include left bundle branch area pacing effectively covering all current forms of conduction system pacing.
Both of these pacemakers treat patients with atrioventricular block.